The $53 Pill That Costs 69 Cents in England

Introduction

Climate Central's March 2026 report found that 173 of 198 U.S. cities, roughly 87%, have longer freeze-free growing seasons than they did in 1970 — an average of 21 extra days of pollen. Plants produce about 20% more pollen than they did 50 years ago. The CDC puts 25.7% of U.S. adults and 18.9% of children in the seasonal allergy bucket, and the AAFA's 2026 Allergy Capitals report confirms the trend is not regional. Numerator's May 2024 survey found 64% of U.S. households bought allergy medication in the past year, spending an average of $58 across three or four trips to the pharmacy.

That medicine — cetirizine, the active ingredient in Zyrtec — sells for 69 pence per 30-tablet pack at a British discount pharmacy. The same count runs about $53 at a U.S. drugstore. The patent on cetirizine expired over two decades ago. The molecule is the same on both shelves. The 60x gap has nothing to do with longer pollen seasons or harder-to-manufacture chemistry. It traces to a structural decision made in 2002 that no American institution has had any reason to unmake — and every spring that allergy season gets longer, more people pay the price for it.

What the Paper Trail Says About 2002

Claritin was a $2.7 billion product for Schering-Plough in 1999, generating nearly a third of the company's total revenue and over 40% of the antihistamine market, per Pharmaceutical Online. The compound patent was set to expire on June 19, 2002. U.S. market exclusivity ended December 19, 2002. Generic loratadine was coming, and it was going to take most of that revenue with it.

Schering-Plough's first response to the patent cliff was to spend heavily on blocking it. Public Citizen's 2000 investigation documented that the company spent $9.2 million on federal lobbying in 1999 alone, more than any other drug company, double its 1998 spending. Between 1996 and 2000, Schering-Plough funneled $19.9 million into lobbying and campaign contributions. The goal was a three-year patent extension that Public Citizen calculated would have cost consumers $7.3 billion. The seven Senate Judiciary Committee co-sponsors of the extension bill collected $74,998 from Schering-Plough, 17 times more than the $4,300 that went to the committee's other 16 members. The lobbyist roster included Linda Daschle, wife of the Senate Minority Leader.

The patent extension failed, and the reversal followed. The push for an OTC switch had actually started from outside: Blue Cross of California filed an FDA citizen petition in July 1998 demanding the reclassification — the first time an insurer had petitioned for a drug's OTC conversion. Schering-Plough, along with Pfizer and Aventis, opposed it. The FDA advisory committee sided with the insurer in May 2001. With the regulatory outcome no longer in doubt and market exclusivity expiring in December 2002, Schering-Plough filed its own OTC application in March 2002 — nine months before exclusivity ran out — and got FDA approval on November 27, the same switch it had been opposing for four years. The FDA approved on November 27, 2002, per PBS NewsHour coverage at the time. Because the application was filed first, Claritin became the only non-drowsy OTC antihistamine on shelves at launch. Zyrtec and Allegra stayed prescription-only for years, and generic prescription loratadine couldn't be sold over the counter without its own OTC application. The "consumer access" framing showed up in press releases only after the revenue math flipped.

Schering-Plough also quietly launched Clarinex (desloratadine), a minor metabolite of loratadine with no clinically meaningful difference, as a prescription follow-on aimed at insured patients. ABC News called it "Old Drug Disguised as New?" in its contemporaneous coverage. First-month OTC Claritin sales hit $105 million, roughly three times the prior-year OTC quarterly total of $53 million, per the Schering-Plough Q4 2002 earnings release. The pricing floor Schering-Plough set that November is still the floor Bayer defends on the Claritin box today.

The 17 Years Nobody Noticed

When Claritin went OTC in late 2002, health insurers responded by removing it from formularies. A 2005 BMJ study that surveyed 12 managed care organizations found every single one dropped loratadine from its drug lists and raised copayments for the prescription antihistamines still covered. The cost moved from the insurer's ledger to the patient's wallet; a $10 copay became full OTC retail overnight.

Then the IRS rule locked it in. From 2003 onward, Section 213(d) excluded OTC medicines from HSA and FSA reimbursement unless a doctor wrote a prescription for them, which defeated the entire point of the OTC switch. That exclusion stayed in place until the CARES Act of March 27, 2020, which amended 213(d) retroactive to January 1, 2020. For 17 consecutive years, OTC allergy medicine sat outside every U.S. drug-pricing lever that matters: no formulary inclusion, no PBM rebate negotiation, no step therapy, no pre-tax reimbursement.

The U.S. does not regulate drug prices directly. What compresses Rx prices is payer pressure, the PBM threatening to drop a product from a formulary unless the manufacturer rebates back. Remove the payer and the pressure goes with it. For 17 years, Bayer and Johnson & Johnson marketed Claritin and Zyrtec into a market where the only counterweight was a shopper deciding between the brand box and the store generic three feet away. CARES eventually let people pay with pre-tax dollars, but by then the pricing culture was cemented.

How the Rest of the World Prices the Same Molecule

Boots, the UK's largest pharmacy chain, sells its own-brand cetirizine at £5.99 for 30 tablets. At Savers, a UK discount retailer, the same 30-tablet pack runs 69p, about three pence per tablet. PharmacyChecker's international database lists generic loratadine as low as $0.22 per tablet in bulk packs. A 30-count brand-name Zyrtec at a U.S. drugstore runs around $53 at full retail, per SingleCare's pricing data. The ratio between U.S. brand retail and UK discount generic is roughly 60 to 1.

Markup explains some of the gap, but the structural differences explain more. The UK bans direct-to-consumer pharmaceutical advertising; the U.S. is one of only two countries that allow it. J&J spent close to $1 billion marketing Zyrtec since its 2008 OTC launch, a cost nobody would absorb without a back-end recoup, and Bayer's Claritin TV spend in March 2024 alone hit $9.6 million. The NHS operates as a single buyer negotiating formulary-level prices, which the U.S. system has no equivalent of. On top of that, slotting fees, the payments manufacturers make to retailers for shelf placement, can reach $250,000 per item in premium markets; large brands can afford them, store brands and new entrants frequently cannot, and the DOJ has flagged the practice as a structural barrier to entry.

Who Benefits

The brand manufacturers take the top slice. Kenvue's 2024 earnings release shows $15.455 billion in total net sales, a 58% gross profit margin, and a Self Care segment that generates $6.527 billion on a 33.3% adjusted operating margin. That segment holds Zyrtec, Tylenol, Nicorette, and Benadryl; Kenvue describes Zyrtec as the "#1 allergy brand in the U.S." and the company spent more than 40% of net sales on SG&A in 2024. A margin that rich on a molecule that costs pennies to synthesize depends entirely on shoppers continuing to pick the label over the identical generic next to it. Bayer paid $14.2 billion for Merck's consumer care division in 2014 with Claritin as a centerpiece, a valuation that assumes the brand premium outlasts the patent by decades.

Retailers collect on both ends of the aisle. A shelf displaying Zyrtec at $53 next to Equate at $18 moves both products, and the retailer wins either way: it collects slotting fees from Bayer for the premium placement and pockets margin on a private-label generic manufactured at commodity cost. Walmart's Equate holds 11.7% of the market per Numerator, sitting right alongside Zyrtec's 13.2% and Claritin's 13.0%.

Insurers benefit from the cost shift. Every drug that moves from Rx to OTC comes off their formulary, which means they stop paying for it and the patient absorbs the difference. The BMJ study found all 12 of the insurers it surveyed did exactly that the year Claritin switched, which aligns the payer's financial incentive squarely behind more OTC switches.

The original architect benefited most. Schering-Plough turned a patent cliff into a $105-million first month and preserved brand identity long enough to pivot loyal prescribers to Clarinex before generics fully penetrated. Merck acquired the company in 2009, a deal only payable because the Claritin OTC playbook had already worked.

One Merger, No Policy Fix

On April 16, 2026, Kimberly-Clark announced its post-close leadership team for its $48.7 billion acquisition of Kenvue. Shareholders on both sides approved the deal in January 2026 (96% of KMB shares, 99% of KVUE shares), and the FTC is still running a second-request review. When it closes in H2 2026, the company that owns Zyrtec will also own Kleenex, Huggies, Kotex, and Cottonelle. Analysts are projecting $2.1 billion in net combined cost savings within four years. The FTC's focus is on baby care and feminine care overlap, not the allergy aisle, which means the allergy brand is going to end up sitting inside a much larger conglomerate with much more retail negotiating power.

There is no public evidence the merger will raise Zyrtec prices directly. What it will do is concentrate far more retail-facing power inside the company that owns the country's #1 allergy brand, at the moment the pricing structure already gives the manufacturer the upper hand every spring.

The current HHS secretary has said publicly that rising childhood allergy rates are a national chronic-disease priority, and MAHA's first commission report lists allergy and autoimmune disorders as leading drivers. The administration's drug pricing plan is "most favored nation" for brand prescription drugs, and Kennedy has explicitly said he won't touch pharmaceutical patents. OTC allergy medicine, the category 50 million Americans actually pay for out of pocket, does not appear on any published policy list.

Next Switch, Same Playbook

No U.S. mechanism is currently set up to compress this pricing. The FDA's reauthorized OTC Monograph User Fee program requires the agency to issue guidance by November 2026 on which Rx drugs are good candidates for OTC switches, which means more switches are in the pipeline. Unless the pricing rules get rewritten before those drugs land, the next off-patent blockbusters will run the same playbook.